23 February, 2018
For the first time Ziccum CEO Göran Conradsson presents the story of LaminarPace to investors and analysts at Stockholm's prestigious Erik Penser Bank, Stockholm, March 15, 1200. But book early. Seats are limited.
20 February, 2018
Approx. 450 human antibodies are currently being developed to treat a wide range of diseases—but many are formulated as liquids, risking instability and attrition in clinical trials. Ziccum AB now releases full data from its recent proof-of-concept test showing how LaminarPace dries human antibodies into stable, active dry powders. The data include SEM (Scanning Electron Microscope) images, and more.
19 February, 2018
80% of human immunoglobulin antibodies, used to treat a wide range of diseases, are formulated as liquids, which can mean they are fragile, unstable and costly to transport. New results show that Ziccum AB’s spray drying instrument LaminarPace can produce a stable dry powder form of immunoglobulin antibodies—with confirmed activity. ‘This is an important milestone,’ says Ziccum CEO Göran Conradson.
26 January, 2018
Inhalation Sciences dotterföretag Ziccum AB har erhållit lån om 2 MSEK för att accelerera affärsutvecklingsaktiviteterna. Vidare meddelas att Ziccum AB förbereder för notering vid Aktietorget under fjärde kvartalet 2018 och att Inhalation Sciences aktieägare kommer att erbjudas förtur till deltagande i den planerade noteringsemissionen.